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Abstract
Objecti6e: To compare waiting times for percutaneous transluminal coronary angioplasty
(PTCA) and coronary artery bypass graft (CABG) surgery in New York State, the
Netherlands and Sweden and to determine whether queuing adversely affects patients’
health. Methods: We reviewed the medical records of 4487 chronic stable angina patients
who underwent PTCA or CABG in one of 15 New York State hospitals (n1021) or were
referred for PTCA or CABG to one of ten hospitals in the Netherlands (n1980) or to one
of seven hospitals in Sweden (n1486). We measured the median waiting time between
coronary angiography and PTCA or CABG. Results: The median waiting time for PTCA in
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New York was 13 days compared with 35 and 42 days, respectively, in the Netherlands and
Sweden (PB0.001). For CABG, New York patients waited 17 days, while Dutch and
Swedish patients waited 72 and 59 days, respectively (PB0.001). The Swedish and Dutch
waiting list mortality rate was 0.8% for CABG candidates and 0.15% for PTCA candidates.
Conclusions: There were large variations in waiting time for coronary revascularization
among these three sites. Patients waiting for CABG were at greatest risk of experiencing an
adverse event. In both the Netherlands and Sweden, the capacity to perform coronary
revascularization has been expanded since this study began. Further international coopera-
tion may identify other areas where quality of care can be improved. © 1997 Elsevier Science
Ireland Ltd.
Keywords: Coronary artery bypass graft surgery; Percutaneous transluminal coronary angio-
plasty; Quality of health care; Health policy; Waiting list
1. Introduction
Coronary artery disease is a major cause of death and morbidity in the Western
World. Although our ability to treat coronary artery disease with coronary artery
bypass graft surgery (CABG) and percutaneous transluminal coronary angioplasty
(PTCA) has improved with time, both are complex and expensive procedures, and
these procedures have been closely regulated in many locales. This regulation has
often focused on limiting the number of interventional cardiothoracic centers in
order to increase procedural volume and decrease complications and cost per
procedure [1–5]. An issue that has not been well examined is whether such
regulation limits access to these services. Excessive delays in access may decrease
the quality of care. Conversely, if treatment capacity is such that everyone can be
treated immediately, some have argued that there may be a tendency to increase the
use of resources by expanding the indications for these procedures beyond what is
supported by the literature [6,7]. The optimal situation maybe in between, with
active management of access to high technology services such as CABG and PTCA
providing efficient use of these services without affecting quality of care [8].
Active management, which usually limits access by some means of rationing,
occurs in countries with both universal and non-universal health care systems. In
the United States, a country without universal health care, one frequently sees
implicit rationing with insured patients having ready access to care while uninsured
patients are denied access or receive delayed care [9]. In Canada and Western
Europe, where patients have universal access to care, a more visible form of
rationing occurs through the use of waiting lists [8,10–12]. There have been few
comparative studies on the outcome of care provided through such systems. As the
United States moves towards managed care and some European countries try to
add free market policies to their national health insurance systems, understanding
the consequences of these different means of restricting access takes on added
importance.
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We report here on the waiting time for chronic stable angina patients undergoing
either PTCA or CABG in New York State, Sweden and the Netherlands. We assess
the frequency of major adverse events among the Swedish and Dutch patients. By
focusing on patients with a relatively homogeneous clinical condition, this approach
reduces the bias of cross-national differences in the types of patients referred for
these procedures. The inclusion of patients from a representative sample of cases at
these three sites suggests that the results are generalizable.
2. Methods
2.1. Patient populations
We examined waiting times from coronary angiography to PTCA and CABG in
New York State, Sweden and the Netherlands. These data were originally collected
to assess the appropriateness of use of PTCA and CABG at each of these sites
[13–16]. In order to assure that differences in waiting time reflected differences in
styles of practice (e.g., urgency of the procedure) and not differences in the type of
patients undergoing the procedure (e.g., the proportion of patients presenting with
unstable angina vs. chronic stable angina vs. acute myocardial infarction) we
restricted these analyses to one group of patients present in all three datasets,
chronic stable angina patients who had not previously undergone bypass surgery.
The definition of chronic stable angina was the same at all three sites.
In New York State, we obtained data on 2694 patients randomly sampled from
15 New York State hospitals who underwent PTCA or CABG in 1990 [13,15]. For
this report we excluded all patients who presented with conditions other than
chronic stable angina (n1504), patients who had previously undergone CABG or
in whom CABG was to be combined with valvular heart surgery (n139), and
those for whom the date of the coronary angiography was not known (n30). The
final sample consisted of 457 PTCA patients and 564 CABG patients.
In the Netherlands, we prospectively collected data on patients referred for
consideration of coronary revascularization to 10 of the 13 heart centers in the
Netherlands [14]. Enrollment in the study began between February and September
1992, depending on the center, with the goal of enrolling a consecutive sample of
patients from each center. Enrollment at each center was stopped after one quarter
of the expected yearly cases were enrolled. Patients who had previously undergone
CABG or in whom CABG was to be combined with other surgery were excluded.
We enrolled 3980 patients. For this report, we excluded patients for whom it was
decided to continue medical management (n757) since they were not referred for
revascularization following coronary angiography. PTCA and CABG candidates
who presented with a condition other than chronic stable angina (n1232) or with
concurrent non-cardiac terminal disease (n11) were also excluded. Our final
sample included 919 PTCA patients and 1061 CABG patients. For analyses of
waiting time, which were restricted to patients who actually underwent the proce-
dure to allow comparability with the other datasets, we excluded patients for whom
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either the date of their coronary angiography or coronary revascularization proce-
dure was missing (n38), and patients who were switched to medical therapy
(n75), dropped out of the study (n5) or died (n13) leaving 869 PTCA
patients and 980 CABG patients.
In Sweden, we prospectively collected data on patients referred for consideration
of coronary revascularization to seven of the eight public Swedish heart centers. We
enrolled patients between September 1, 1994 through January 15, 1995 for 6 centers
and May through October 1994 for one center, with the goal of enrolling a
consecutive sample of at least 2400 patients. Patients who had previously under-
gone CABG or in whom CABG was to be combined with other surgery were
excluded. We enrolled 2878 patients. For this report, we also excluded patients for
whom it was decided to continue medical management (n730); those who were
judged too ill, by their physician, to participate (n47), and those presenting with
conditions other than chronic stable angina (n615). Our final sample included
447 PTCA patients and 1039 CABG patients. For analyses of waiting time, we
excluded patients for whom either the date of their coronary angiography or
coronary revascularization procedure was missing (n9) and patients who with-
drew from the list (n45) or who died (n8) leaving 423 PTCA patients and 1001
CABG patients.
2.2. Data collection and analysis
Similar abstraction forms were created for each of the three sites to collect each
patient’s relevant clinical and laboratory information. Data included the patients
sociodemographic characteristics, the extent of coronary artery disease and clinical
features. In New York State, data were collected retrospectively while in Sweden
and the Netherlands prospective data collection began at the first meeting in the
heart center in which the patients case was discussed following coronary angiogra-
phy. Data were reviewed for completeness and accuracy before being entered into
the computerized data base. Additional details regarding the way cases were
selected, data collected and confidentiality maintained are described elsewhere
[13–15].
Waiting time was defined as the number of days between the date of coronary
angiography and the date of CABG or PTCA. Data regarding adverse events (e.g.,
death and complications) that occurred on the waiting list are available for the
Netherlands and Sweden. No data on adverse waiting list events are available for
New York State patients since the New York data were collected retrospectively
and only included those patients who underwent PTCA and CABG; consequently,
patients who died while waiting for PTCA or CABG can not be identified.
We used the STATA (version 5.0) statistical package for all analyses. Categorical
variables were analyzed by the Chi-square test. We use nptrend, which is an
extension of the Wilcoxon rank-sum test, to test for trend across ordered groups
[17]. As waiting times were not normally distributed, we report the median waiting
time, show the interquartile range (25–75%), and test whether the median waiting
times were equivalent between groups using the Kruskal-Wallis statistic. To test
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which pairs of groups have different waiting times when the Kruskal-Wallis statistic
indicated an overall difference, we use the Dunn Procedure [18]. To see if there was
a significant difference in time to death for patients on the waiting list, we
compared survival curves for equality using the Mantel-Haenszel test.
3. Results
We studied the care received by 1021 patients in New York State, 1424 patients
in Sweden and 1849 patients in the Netherlands who underwent CABG or PTCA
(Table 1). In New York State, almost one-quarter of all PTCAs were performed in
patients younger than age 50 compared with 17% of such procedures in Sweden and
the Netherlands (P0.03). For bypass surgery, a greater proportion of procedures
were performed in patients over the age of 75 in New York State (12%) compared
with Sweden and the Netherlands (9% and 8%, respectively; P0.01). There was
no significant difference between the three sites in the proportion of patients who
were women; they represented approximately one-quarter of the patients undergo-
ing PTCA and one-fifth of those undergoing bypass surgery.
3.1. Waiting time for PTCA
Patients undergoing PTCA in New York State waited a median of 13 days
compared with 42 and 35 days, respectively (PB0.001), for Swedish and Dutch
patients (Table 2). There was a linear trend toward decreasing waiting time with
increasing age in the Netherlands (P0.01), with the median wait decreasing from
38 days for patients under the age of 65, to 16 days for those of 75 years or older,
but not for the other two sites. Although women waited for fewer days compared
with men in the Netherlands, this finding was not significant. In the Netherlands,
patients with more severe angina (i.e., Canadian Cardiovascular Society Class III or
IV) had shorter waiting times than those with milder angina (PB0.01) with the
median waiting time decreasing from 50 to 30 days.
3.2. Waiting time for CABG
Although patients undergoing bypass surgery waited longer than those undergo-
ing PTCA at all three sites (Table 3), this was significant only in Sweden where their
median waiting time 40% longer (PB0.001) and in the Netherlands where they
waited twice as long (PB0.001). Bypass patients in New York State waited only 17
days compared with 59 days in Sweden (PB0.001) and 72 days in the Netherlands
(PB0.001). Waiting time decreased with age in both New York State (PB0.05)
and the Netherlands (PB0.01). Patients with left main coronary artery disease had
the shortest waiting times but these patients waited about three times longer for
their procedures in Sweden (34 days) and the Netherlands (21 days) than in New
York State (6 days; PB0.01 for both comparisons). We found no difference in
waiting times between patients with three vessel disease and those with one or two
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vessel disease at any of the sites. Angina class was a significant factor in waiting
time only for Dutch patients. Those with more severe angina waited approximately
30 days less than those with milder angina (PB0.01).
3.3. Ad6erse e6ents on waiting lists
In this section we review the adverse events that occurred to Swedish and Dutch
patients on the waiting list. Unfortunately, since the New York State data were
collected retrospectively, we have no relevant information for New York patients.
In Sweden, eight of the 1039 candidates for bypass surgery died while waiting for
the procedure but none of the 447 referred for PTCA died. Of the patients who
died, seven had a cardiac related event. Two of these patients had left main disease,
five had three vessel disease, and one had two vessel disease. At the time the
patients were reviewed for revascularization, their physicians estimated the urgency
of bypass surgery; however, there were no formal guidelines for selection of patients
for revascularization or for determining waiting list priority. Patients were classified
as needing bypass surgery within one week, between 1 and 4 weeks or between 1
and 3 months. Two patients died after waiting longer than their assigned urgency
rating: one was classified as needing bypass surgery within 4 weeks and died on day
Table 2
Median number of days of waiting for chronic stable angina patients undergoing PTCA by site
New York State Sweden NetherlandsCharacteristic
(25,75)aMedian (25,75)a Median (25,75)a Median
(11,71)13Overall* (3,42) 42 (20,63) 35
Age (years)
(15,61)35(2,35) (12,76)**10B50 38
(13,76)50–64 16 (4,47) 42 (21,62) 38
12 (3,35) 4865–74 (19,67) 30 (9,64)
(3,36)11 (8,64)16(29,73)]75 42
Sex
41(3,41) (13,76)13Male 37(19,61)
(8,62)(3,50)Female 4814 (29,79) 26
Anatomic disease
7 (2,22)Left main – (–)29(–)
(10,71)36Three vessel 18 (5,53) 45 (20,79)
34(19,61)42 (11,71)(3,41)12One or two vessel
75 (28,124) 51 (28,80) 53 (12,85)Non-significant
Angina class
(21,86)***15Class I or II (6,45) 48 (24,71) 50
(9,68)(3,36) 42Class III or IV (16,59)12 30
aInterquartile range.
*PB0.001 (New York State vs. Sweden; New York State vs. the Netherlands).
**P0.01 (Netherlands: decreasing waiting time with age (by nptrend)).
***PB0.01 (Netherlands: Canadian Cardiovascular Society Angina Class I:II vs. III:IV).
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Table 3
Median number of days of waiting for chronic stable angina patients undergoing CABG by site
NetherlandsSwedenNew York StateCharacteristic
(25,75)aMedian (25,75)a Median (25,75)a Median
(30,91)**Overall 7217 (22,122)(6,41)* 59
Age (years)
(33,84) 82 (24,139)***B50 15 (5,45)** 53
(33,123)7850–64 20 (31,93)(7,41) 62
(17,122)65–74 15 (6,42) 57 (31,85) 66
(18,86)]75 10 (4,30) 56 (25,98) 38
Sex
72 (22,120)Male (33,91)16 (6,40) 60
(19,128)Female 20 (7,46) 53 (26,91) 72
Anatomic disease
21 (10,64)†Left main (17,63)†5 (2,17)† 34
86Three vessel 21 (8,42) 66 (36,94) (36,131)
(22,126)One or two vessel 24 (8,61) 68 (35,95) 78
(49,98)Non-significant – 85– (55,204)78
Angina class
96Class I or II 17 (6,42) 60 (30,90) (42,133)‡
(19,116)Class III or IV 18 (5,40) 57 (30,91) 64
aInterquartile range.
*PB0.001 (New York State vs. Sweden; New York State vs. Netherlands).
**PB0.01 (Netherlands vs. Sweden).
***PB0.01 (Netherlands: decreasing waiting time with age (by nptrend)).
†PB0.01 (New York State, Sweden and the Netherlands: left main vs. non-left main disease).
‡PB0.01 (Netherlands: Canadian Cardiovascular Society Angina Class I:II vs. III:IV).
48; the second was to be treated within 3 months and died on day 119. The
remaining six patients died before the maximum recommended waiting time.
In the Netherlands, 11 of the 1061 chronic stable angina candidates for bypass
surgery died. Eight of these patients had an established cardiac related event. One
of these patients had left main disease, five had three vessel disease and two had
two vessel disease. Patients were classified as needing bypass surgery within one
day, one week, between 1 and 4 weeks or between 1 and 3 months. Two patients
classified as needing bypass surgery within 3 months died after waiting 116 and 176
days, respectively. The remaining patients died before their maximum recom-
mended waiting time. There was no significant difference in the time to death
between Dutch and Swedish patients (P0.49).
An additional eight Dutch patients suffered a non-fatal myocardial infarction, 65
patients had worsening of their angina and 26 had improvement of their anginal
symptoms. Some patients urgency status was reclassified due to a change in their
symptoms. For example, the number of bypass candidates considered emergencies
more than doubled from the time patients were placed on the list (from seven to 17)
and there was a 25% increase in the number of bypass cases considered urgent
(from 239 to 296). Overall, for 9% of Dutch CABG candidates the urgency rating
was changed.
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For PTCA, two of the 919 Dutch candidates died and four suffered a non-fatal
myocardial infarction while waiting for the procedure. Thirty-one patients had
improvement of their angina and 34 had worsening of their angina. Only three
PTCA candidates had their urgency status changed to emergent and 27 were
reclassified as urgent while waiting. Overall, for 5% of the PTCA candidates the
urgency rating was changed.
4. Discussion
There are two major findings from this study. First, waiting times for PTCA and
CABG were significantly shorter in New York State than in Sweden and the
Netherlands. Second, there were few adverse events among those patients put on a
waiting list for PTCA but one percent of those waiting for bypass surgery died.
Why do the waiting times differ to such a degree between countries? There are at
least three potential factors that could account for these differences including:
1. a differential effect of patient clinical characteristics on waiting time;
2. the accessibility of health care and the capacity to perform coronary revascular-
ization; and
3. consumer and physician attitudes.
Patients with left main coronary artery disease had significantly shorter waiting
times at all three sites, but increased anginal severity only affected waiting times for
Dutch patients, where a worsening of angina from Class I or II to Class III or IV
led to a 40% decrease in waiting time for both PTCA and CABG. Age also had a
differential effect on waiting time, with decreasing waiting time with increasing age
for both Dutch and New York CABG patients and in Dutch PTCA patients. Thus,
cross-national differences in the weight given these clinical characteristics may
explain partly the differences in waiting time.
Was access similar at these three sites? No. Many Americans are either uninsured
or underinsured. In a 1993 poll it was found that 12% could not get medical care
in the previous year and 30% delayed seeking medical care because they could not
afford it [19]. Five percent of US physicians reported that they had difficulty
obtaining complex surgical procedures, such as CABG, for their patients at least
three times in 1991 [20]. The two most common reasons cited were lack of health
insurance to cover payment and that the patients could not afford the health care
costs. In contrast, there were no financial barriers to health care in Sweden and the
Netherlands. However, merely having access to a health care system doesn’t assure
patients of access to high-technology procedures such as PTCA and CABG since
the number of cardiothoracic surgical units, and therefore treatment capacity, was
limited by the government at all three sites [21–23]. There was one cardiothoracic
center for every 580 000 people in New York State compared with one center for
every one million people in Sweden and one for every 1.15 million people in the
Netherlands. There were also higher utilization rates for cardiovascular procedures
such as bypass surgery in New York State (92 per 100 000) compared with Sweden
(79 per 100 000) and the Netherlands (61 per 100 000) [22,24]. Thus, treatment
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capacity was substantially higher in New York State given their respective utiliza-
tion rates and this may help explain why the waiting list was comparably short
there.
A third possible reason for differences in waiting time relates to consumer and
physician attitudes towards waiting and health care expenditures. American pa-
tients and physicians may be more reluctant to wait than their European counter-
parts. Almost 60% of Americans thought it was essential or very important to get
elective surgery, such as coronary revascularization for chronic stable angina,
without much delay whereas 72% of Dutch physicians and consumers thought
waiting lists are acceptable, at least sometimes, to regulate access to medical
services [19,25]. With respect to health care expenditures, 69% of the American
public believed that we are spending too little on health care [26] and 77% rejected
even putting a global budget on health care expenditures or expenditures for high
technology goods [19]. In contrast, a 1991 survey in Sweden found that 40%
thought that health care expenditures should be increased while 9% thought that
expenditures should be reduced [27]. The Europeans were more satisfied with their
health care system than the Americans. When asked what type of change was
needed, almost one-third of Americans thought the US health care system needed
to be entirely rebuilt in contrast to about 5% of Swedish and Dutch citizens [28,29].
The differences in waiting times are clinically important. We found that there was
a small but significant risk for those on the bypass surgery queue. For PTCA
candidates, the risk of dying on the waiting list was less than 0.2%. However, the
mortality rate for bypass surgery candidates was 0.8% in both the Netherlands and
Sweden and the rate of death or non-fatal myocardial infarction among the Dutch
patients was 1.8%. In addition, almost 10% of patients had a change in their
symptoms necessitating a change in their urgency status. These rates seem excessive
when compared with the operative mortality rate for patients undergoing CABG at
the time the data were collected of 2.25% in the Netherlands [30] and 3.6% in New
York State [31].
Were these patients all appropriate candidates for CABG and PTCA? For bypass
surgery, where the risk of adverse events on the waiting list is greatest, the
inappropriate rate ranged from 2% in New York State to 8% in Sweden, with 5%
of cases inappropriate in the Netherlands. The appropriateness of PTCA was more
questionable with about 40% of cases at each site judged uncertain in appropriate-
ness [14,15] (Swedish Council on Technology Assessment in Health Care, unpub-
lished data).
There are several limitations to this study. Firstly, we have no data on the
consequences of waiting for coronary angiography, a procedure that is necessary
before considering revascularization. If waiting times for coronary angiography
were excessive, many of the patients who might be adversely impacted by a
prolonged wait for revascularization would already have suffered the consequences.
Secondly, we calculated the waiting time as the period between diagnostic coronary
angiography and coronary revascularization. In reality, patients are not placed on
a waiting list until after the coronary angiography is reviewed and a decision is
made regarding treatment. The overall median difference between the date of
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coronary angiography and the date of the cardiovascular conference where the
decision was made to place the patient on the waiting list was 1 day for Swedish
PTCA and CABG patients, 4 days for Dutch PTCA patients and 6 days for Dutch
CABG patients. Thirdly, we do not have complete data on all adverse events that
occurred. In Sweden we only recorded major events such as mortality while in New
York, the data were collected retrospectively from those patients who received the
procedure and thus we could not study adverse events patients experienced on the
queue. Yet, given the relatively short waiting times in New York, the clinical
similarity of the patients and the rate of occurrence of adverse events in Sweden
and the Netherlands, we doubt that we missed many significant events. We also did
not measure indirect effects of queuing such as possible increased anxiety for
patients and their families. Fourthly, we studied adverse events in chronic stable
angina patients who are at less risk of adverse events then patients with unstable
angina or following a myocardial infarction; however, this allowed us to examine a
more homogeneous population. Fifthly, we studied waiting times between 1990 and
1994; some of the differences we found might reflect a slower diffusion of technol-
ogy in Europe than in the United States. Finally, although our sample was
representative of the Netherlands and Sweden it may not be representative of the
United States. Waiting times and types of patients undergoing CABG and PTCA
may differ between New York and other states with less regulatory environments
[15,32–34].
This study illustrates the advantage of comparing outcomes of care in different
countries to better understand how health care systems affect their citizens. For
bypass surgery, Swedish and Dutch patients waited 42 to 55 days more than New
York State patients (see Table 3), this wait was associated with a small risk of death
or myocardial infarction. However, we did not find a dose-response relationship
between waiting time and the probability of dying on the waiting list. Despite the
shorter waiting period in New York State, we found that New York patients did
not have less severe angina, less coronary artery disease, nor that they had higher
rates of inappropriate use. In fact 76% of the New York patients had left main or
three vessel coronary artery disease compared with 69% and 70% of patients in
Sweden and the Netherlands, respectively.
For PTCA, we also found longer waiting periods in Sweden and the Netherlands
but very few patients experienced adverse events because of this wait. However, the
patients who appeared to have the least severe disease (milder angina and substan-
tially greater incidence of non-significant coronary artery disease) were from
Sweden and not from New York State. Thus the greater capacity to perform these
procedures in New York State was not associated with inappropriate resource
utilization.
Partly in response to these data the Netherlands have decided to expand bypass
surgery capacity [35]. In Sweden and New York State, access to cardiovascular care
continues to be closely monitored. Further international cooperation may identify
other areas where quality of care may be improved.
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